|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/10/22 Lineage Cell Therapeutics, Inc. 10-Q 9/30/22 86:8.4M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.35M
2: EX-10.2 Material Contract HTML 94K
3: EX-10.3 Material Contract HTML 92K
4: EX-10.4 Material Contract HTML 92K
5: EX-10.5 Material Contract HTML 32K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
13: R1 Cover HTML 77K
14: R2 Condensed Consolidated Balance Sheets HTML 146K
15: R3 Condensed Consolidated Balance Sheets HTML 41K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 141K
(Unaudited)
17: R5 Condensed Consolidated Statements of Comprehensive HTML 55K
Loss (Unaudited)
18: R6 Condensed Consolidated Statements of Cash Flows HTML 124K
(Unaudited)
19: R7 Organization and Business Overview HTML 40K
20: R8 Basis of Presentation, Liquidity and Summary of HTML 114K
Significant Accounting Policies
21: R9 Revenue HTML 65K
22: R10 Marketable Debt Securities HTML 42K
23: R11 Marketable Equity Securities HTML 35K
24: R12 Property and Equipment, Net HTML 35K
25: R13 Goodwill and Intangible Assets, Net HTML 52K
26: R14 Accounts Payable and Accrued Liabilities HTML 33K
27: R15 Fair Value Measurements HTML 65K
28: R16 Related Party Transactions HTML 28K
29: R17 Shareholders? Equity HTML 245K
30: R18 Stock-Based Awards HTML 101K
31: R19 Income Taxes HTML 39K
32: R20 Commitments and Contingencies HTML 142K
33: R21 Subsequent Events HTML 32K
34: R22 Basis of Presentation, Liquidity and Summary of HTML 143K
Significant Accounting Policies (Policies)
35: R23 Basis of Presentation, Liquidity and Summary of HTML 58K
Significant Accounting Policies (Tables)
36: R24 Revenue (Tables) HTML 57K
37: R25 Marketable Debt Securities (Tables) HTML 41K
38: R26 Property and Equipment, Net (Tables) HTML 31K
39: R27 Goodwill and Intangible Assets, Net (Tables) HTML 50K
40: R28 Accounts Payable and Accrued Liabilities (Tables) HTML 32K
41: R29 Fair Value Measurements (Tables) HTML 59K
42: R30 Shareholders? Equity (Tables) HTML 217K
43: R31 Stock-Based Awards (Tables) HTML 103K
44: R32 Commitments and Contingencies (Tables) HTML 72K
45: R33 Organization and Business Overview (Details HTML 33K
Narrative)
46: R34 Schedule of Lineage's Ownership of Outstanding HTML 36K
Shares of its Subsidiaries (Details)
47: R35 Schedule of Lineage's Ownership of Outstanding HTML 29K
Shares of its Subsidiaries (Details)
(Parenthetical)
48: R36 Schedule of Anti-dilutive Securities Excluded from HTML 30K
Computation of Earnings Per Share (Details)
49: R37 Schedule of Reconciliation of Cash, Cash HTML 32K
Equivalents, and Restricted Cash (Details)
50: R38 Basis of Presentation, Liquidity and Summary of HTML 75K
Significant Accounting Policies (Details
Narrative)
51: R39 Schedule of Disaggregated Revenues (Details) HTML 51K
52: R40 Schedule of Contract with Customer Contract HTML 29K
Liability and Receivable (Details)
53: R41 Schedule of Contract with Customer Contract HTML 27K
Liability and Receivable (Details) (Parenthetical)
54: R42 Revenue (Details Narrative) HTML 53K
55: R43 Summary of Available for Sale Debt Securities HTML 36K
(Details)
56: R44 Schedule of Amortized cost And Estimated fair HTML 34K
Value (Details)
57: R45 Marketable Debt Securities (Details Narrative) HTML 28K
58: R46 Marketable Equity Securities (Details Narrative) HTML 37K
59: R47 Schedule of Property and Equipment, Net (Details) HTML 38K
60: R48 Property and Equipment, Net (Details Narrative) HTML 28K
61: R49 Schedule of Goodwill and Intangible Assets Net HTML 47K
(Details)
62: R50 Schedule of Goodwill and Intangible Assets Net HTML 37K
(Details) (Parenthetical)
63: R51 Schedule of Intangible Assets Future Amortization HTML 32K
Expenses (Details)
64: R52 Goodwill and Intangible Assets, Net (Details HTML 31K
Narrative)
65: R53 Schedule of Accounts Payable and Accrued HTML 35K
Liabilities (Details)
66: R54 Schedule of Fair Value of Assets and Liabilities HTML 53K
Valued on Recurring Basis (Details)
67: R55 Schedule of Changes in Fair Value (Details) HTML 33K
68: R56 Related Party Transactions (Details Narrative) HTML 28K
69: R57 Schedule of Shareholder?s Equity (Details) HTML 137K
70: R58 Shareholders? Equity (Details Narrative) HTML 86K
71: R59 Schedule of Share-based Compensation, Employee HTML 97K
Stock Purchase Plan, Activity (Details)
72: R60 Schedule of Share-based Compensation, Employee HTML 39K
Stock Purchase Plan, Activity (Details)
(Parenthetical)
73: R61 Schedule of Weighted Average Assumptions to HTML 34K
Calculate Fair Value of Stock Options (Details)
74: R62 Schedule of Stock Based Compensation Expense HTML 31K
(Details)
75: R63 Stock-Based Awards (Details Narrative) HTML 34K
76: R64 Income Taxes (Details Narrative) HTML 38K
77: R65 Schedule of Supplemental Cash Flow Information HTML 32K
Related to Leases (Details)
78: R66 Schedule of Supplemental Balance Sheet Information HTML 59K
Related to Leases (Details)
79: R67 Schedule of Future Minimum Lease Commitments HTML 64K
(Details)
80: R68 Commitments and Contingencies (Details Narrative) HTML 249K
81: R69 Subsequent Events (Details Narrative) HTML 32K
84: XML IDEA XML File -- Filing Summary XML 153K
82: XML XBRL Instance -- form10-q_htm XML 2.21M
83: EXCEL IDEA Workbook of Financial Reports XLSX 168K
9: EX-101.CAL XBRL Calculations -- lctx-20220930_cal XML 191K
10: EX-101.DEF XBRL Definitions -- lctx-20220930_def XML 673K
11: EX-101.LAB XBRL Labels -- lctx-20220930_lab XML 1.26M
12: EX-101.PRE XBRL Presentations -- lctx-20220930_pre XML 939K
8: EX-101.SCH XBRL Schema -- lctx-20220930 XSD 205K
85: JSON XBRL Instance as JSON Data -- MetaLinks 399± 587K
86: ZIP XBRL Zipped Folder -- 0001493152-22-031359-xbrl Zip 357K
Exhibit 10.5
EXECUTIVE PERFORMANCE INCENTIVE BONUS PLAN
Adopted on September 20, 2022
This Executive Performance Incentive Bonus Plan (this “Plan”) was adopted by the Board of Directors (the “Board”) of Lineage Cell Therapeutics, Inc., a California corporation (the “Company”). Unless the Board determines otherwise, the Compensation Committee shall be the administrator of this Plan (the “Administrator”).
Participants and Performance Goals
From time to time, the Administrator may select executives of the Company or its subsidiaries to be eligible to receive cash bonuses under this Plan (“Participants”). For each Participant, the Administrator may establish (1) a target bonus amount (which the Administrator may adjust from time to time), (2) the Company Performance Goals (as defined below) and/or individual performance goals (together, “Performance Goals”), (3) the time period over which the achievement of Performance Goals will be assessed (a “Performance Period”), and (4) the formula(s) for determining the bonuses payable under this Plan. The Administrator shall determine when a Performance Period begins and ends. Performance Goals may be given such weight as determined by the Administrator and may differ among Participants. Performance Goals (and their weighting) and the applicable Performance Period will be conveyed to a Participant in a time and manner determined by the Administrator. The bonus amounts payable under this Plan shall be determined entirely in the discretion of the Administrator.
Subject to any terms contained in any other written agreement between the Participant and the Company or any of its subsidiaries, the payment of a bonus to a Participant under this Plan with respect to a Performance Period is conditioned on the Participant’s continuous employment by the Company or its subsidiary through the date of payment of such bonus, and if a Participant’s employment with the Company or its subsidiary terminates for any reason before such date with respect to a particular Performance Period, then no bonus shall be paid to the Participant for such Performance Period and such Participant shall cease to be a Participant as of the date of termination of their employment. If a Participant was not employed by the Company or its subsidiary (or was not a Participant) for an entire Performance Period, the Administrator may pro rate the bonus payable under this Plan based on the number of days such Participant was employed during such period.
“Company Performance Goals” means performance objectives established by the Administrator for the applicable Performance Period for a Participant that relate to financial and/or operational metrics with respect to the Company or any of its subsidiaries, including the following: developmental, clinical or regulatory milestones; clinical trial results; business development and financing milestones; acquisitions or strategic transactions; revenue; expense levels; total shareholder return; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of the Company’s common stock; economic value-added; sales or revenue milestones; operating income (loss); cash flow (including, but not limited to, operating cash flow and free cash flow); return on capital, assets, equity, or investment; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; publications; reimbursement decisions; working capital; earnings (loss) per share of the Company’s common stock; sales or market share; investor relations milestones; number of customers or units of products sold; and operating income and/or net annual recurring revenue any of the foregoing may be (A) measured in absolute terms or compared to any incremental increase, (B) measured in terms of growth, (C) compared to another company or companies or to results of a peer group, (D) measured against the market as a whole and/or as compared to applicable market indices, (E) measured on a pre-tax or post-tax basis (if applicable), and (F) used to measure the performance of the Company as a whole or a business unit or other segment of the Company, or one or more product lines or specific markets.
C:
C: 1 | Page |
Taxes
Each Participant will be solely liable and responsible for the payment of taxes, penalties and/or interest arising in connection with this Plan or due to any payment to such Participant hereunder.
This Plan is intended to (the maximum extent possible) be exempt from (but in any event comply with) the requirements of Section 409A of the Internal Revenue Code of 1986 (the “Code”). For purposes of Code Section 409A and to the extent applicable, each payment under this Plan is a separate payment (and not one of series of payments) and this Plan may be terminated by the Administrator at any time in accordance with the Code Section 409A plan termination rules.
In the event that it is determined that any payment or distribution of any type to or for a Participant’s benefit made by the Company, by any person who acquires ownership or effective control or ownership of a substantial portion of the Company’s assets (within the meaning of Code Section 280G) or by any affiliate of such person, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise (the “Total Payments”), would be subject to the excise tax imposed by Code Section 4999 or any interest or penalties with respect to such excise tax (and/or would not deductible under Code Section 280G) (such loss of a tax deduction under Code Section 280G and/or excise tax, together with any such interest or penalties, are collectively referred to as the “Excise Tax”), then such payments or distributions or benefits shall be reduced and shall be payable only as to the maximum portion of such lesser amount which would result in no portion of such Total Payments being subject to the Excise Tax. Any determination required with respect to the foregoing shall be made in writing by the Company or by a qualified accountant or counsel selected by the Company (the “Accountant”) whose determination shall be conclusive and binding on the Company and each Participant, absent manifest error. Each Participant and the Company shall furnish the Accountant such documentation and documents as the Accountant may reasonably request in order to make its determination.
Miscellaneous
The validity, interpretation, construction and performance of this Plan shall be governed by the laws of the State of California without regard to its conflicts of law principles.
The terms of the Plan are subject to any other written agreement between Participant and the Company. In the event of a conflict between this Plan and any such written agreement, the terms of such written agreement will govern.
The Administrator shall have the sole discretion and authority to administer and interpret this Plan and to take such actions it deems necessary or advisable for the administration of the Plan, including, without limitation, to determine the rights and obligations of the Company and Participants under this Plan in the event this Plan is terminated during a Performance Period or a change of control of the Company occurs. The Administrator may amend or terminate the Plan (or make bonus payments outside of this Plan) at any time in its discretion. The Administrator’s decisions and determinations under the Plan shall be final, conclusive and binding on all persons.
This Plan is not an employment agreement and does not give any Participant the right to be retained by the Company or any of its subsidiaries and every Participant acknowledges and agrees that Participant’s employment is “at-will.” The Company reserves the right to terminate the Participant’s service as an employee at any time and for any reason or no reason.
All amounts payable under this Plan are unfunded and unsecured and are payable out of the general funds of the Company.
*****
C:2 | Page |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/10/22 | 8-K | ||
| For Period end: | 9/30/22 | 8-K/A | ||
| 9/20/22 | 8-K, 8-K/A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/07/24 Lineage Cell Therapeutics, Inc. 10-K 12/31/23 104:14M Donnelley … Solutions/FA 4/27/23 Lineage Cell Therapeutics, Inc. 10-K/A 12/31/22 12:719K M2 Compliance LLC/FA 3/09/23 Lineage Cell Therapeutics, Inc. 10-K 12/31/22 105:11M M2 Compliance LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/07/22 Lineage Cell Therapeutics, Inc. 8-K:5,9 7/05/22 11:259K M2 Compliance LLC/FA 8/12/19 Lineage Cell Therapeutics, Inc. 8-K:5,8,9 8/09/19 3:225K M2 Compliance LLC/FA 5/10/18 Lineage Cell Therapeutics, Inc. 10-Q 3/31/18 67:3.5M M2 Compliance LLC/FA |